1-4 of 4
Rekha Pal, PhD
Close
Sort by
Journal Articles

C/EBPb Is a Critical Mediator of Resistance to IMiD® Immunomodulatory Compounds and Affected by IMiD Compounds Via Control of Protein Translation

Shirong Li, PhD, Rekha Pal, PhD, Sara Monaghan, MD, Peter Schafer, PhD, Hongjiao Ouyang, DDS, PhD, Markus Y Mapara, MD, PhD, Suzanne Lentzsch, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 135.
https://doi.org/10.1182/blood.V116.21.135.135
Published: 2010
Journal Articles

Lenalidomide Shuts Down the Translational Machinery in Multiple Myeloma Cells Resulting in Down-Regulation of Critical Transcription Factors Such as C/EBPβ and IRF4.

Shirong Li, PhD, Rekha Pal, PhD, Deborah L Galson, Ph.D., Peter H Schafer, PhD, Hongjiao Ouyang, DDS, PhD, Markus Y Mapara, MD, PhD, Suzanne Lentzsch, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1844.
https://doi.org/10.1182/blood.V114.22.1844.1844
Published: 2009
Journal Articles

C/EBPβ Is a Critical Factor for Proliferation and Apoptosis in MM Cells by Controlling Transcription Factors Like IRF-4, PAX5 and Blimp1.

Rekha Pal, PhD, Martin Janz, PhD, Deborah Galson, PhD, Suzanne Lentzsch, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 1506.
https://doi.org/10.1182/blood.V110.11.1506.1506
Published: 2007
Journal Articles

Cathepsin G, a Potent Platelet Aggregation Activator, Is Upregulated in Multiple Myeloma Patients during Treatment with Lenalidomide (Revlimid).

Rekha Pal, PhD, Ryan Kennedy, L. Renee Mansour, David Stirling, PhD, Markus Y. Mapara, MD, PhD, G. David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2504.
https://doi.org/10.1182/blood.V110.11.2504.2504
Published: 2007